PAPER Licker V, Turck N, Kövari E, Burkhardt K, Côte M, Surini-Demiri M, Lobrinus JA, Sanchez JC, Burkhard PR

Proteomic analysis of human substantia nigra identifies novel candidates involved in Parkinson's disease pathogenesis.

Proteomics. 2014 Mar;14(6):784-94. Epub 2014 Feb 18 PubMed: 24449343

PAPER Raz Y, Adler J, Vogel A, Scheidt HA, Häupl T, Abel B, Huster D, Miller Y

The influence of the ΔK280 mutation and N- or C-terminal extensions on the structure, dynamics, and fibril morphology of the tau R2 repeat.

Phys Chem Chem Phys. 2014 May 7;16(17):7710-7. PubMed: 24448233

PAPER Torres-Platas SG, Comeau S, Rachalski A, Bo GD, Cruceanu C, Turecki G, Giros B, Mechawar N

Morphometric characterization of microglial phenotypes in human cerebral cortex.

J Neuroinflammation. 2014 Jan 21;11:12. PubMed: 24447857

PAPER Su X, Chen Q, Chen W, Chen T, Li W, Li Y, Dou X, Zhang Y, Shen Y, Wu H, Yu C

Mycoepoxydiene inhibits activation of BV2 microglia stimulated by lipopolysaccharide through suppressing NF-κB, ERK 1/2 and toll-like receptor pathways.

Int Immunopharmacol. 2014 Mar;19(1):88-93. Epub 2014 Jan 18 PubMed: 24447679

PAPER Karki P, Smith K, Johnson J Jr, Lee E

Astrocyte-derived growth factors and estrogen neuroprotection: role of transforming growth factor-α in estrogen-induced upregulation of glutamate transporters in astrocytes.

Mol Cell Endocrinol. 2014 May 25;389(1-2):58-64. Epub 2014 Jan 18 PubMed: 24447465

PAPER Khoo HM, Kishima H, Hosomi K, Maruo T, Tani N, Oshino S, Shimokawa T, Yokoe M, Mochizuki H, Saitoh Y, Yoshimine T

Low-frequency subthalamic nucleus stimulation in Parkinson's disease: A randomized clinical trial.

Mov Disord. 2014 Jan 21; PubMed: 24449169

PAPER Kaul S, Elble RJ

Impaired pentagon drawing is an early predictor of cognitive decline in Parkinson's disease.

Mov Disord. 2014 Mar;29(3):427-8. Epub 2014 Jan 21 PubMed: 24449089

PAPER Mendzelevski B, Sprenger CR, Spiegelstein O, Rabinovich-Guilatt L

Cardiac safety of rasagiline, a selective monoamine oxidase type B inhibitor for the treatment of Parkinson's disease: a thorough QT/QTc study.

Int J Clin Pharmacol Ther. 2014 Mar;52(3):192-201. PubMed: 24447649

Greg Sutherland

University of Sydney
Sydney

Kee Hyung Park

Gachon University Collage of Medicine
Incheon, Korea, Republic of

Stephanie Paulovichi

Ann Robbins

Ann Robbins LLC
Bradenton, United States

PAPER Cervenakova L, Brown P, Sandoval F, Foncin JF, Garruto R, Polinsky RJ, Nee L, Goldfarb L

Identification of presenilin-1 gene point mutations in early-onset Alzheimer's disease families

Am J Hum Genet. 1996;59(Suppl):A252

PAPER Mehrabian s, Traykov LT, Jordanova A, Rademakers R, Cruts M, Raycheva MR, Van den Broeck M, Kremensky I, Van Broeckhoven C

Novel PSEN1 gene mutation in a large Bulgarian pedigree with Alzheimer's disease and atypical phenotype

Eur J Neurol. 2006;13(Suppl 2):41.

PAPER Sorbi S, Tedde A, Nacmias B, Ciantelli M, Caffarra P, Ghidoni E, Bracco L, Piccini C

Novel presenilin 1 and presenilin 2 mutations in early-onset Alzheimer's disease families

Neurobiol Aging. 2002; 23(Suppl 1):S312.